Protoporphyrin IX (PpIX) is used as a photosensitizer in the photodynamic diagnosis (PDD) and photodynamic therapy (PDT) of cancer and is synthesized intracellularly from 5-aminolevulinic acid (5-ALA) precursors. Thirteen novel 5-ALA derivatives were designed and synthesized appropriately with tailored hydrophilicity and lipophilicity. The generation of PpIX was detected and their antitumor activity in vitro and in vivo was also investigated. It was shown that compounds 9b–c, 11b–c and 13a displayed a characteristic long wavelength absorption peak at 593 nm after 5 h incubation in mice fibrosarcoma S180 cells. After being exposed to 600 nm laser light irradiation, these compounds can inhibit cell proliferation in S180 cells in vitro. The growth of S180 cell tumors in Kunming mice was significantly inhibited by these compounds in vivo. Among these compounds, 13a has low dark toxicity and high phototoxicity, which makes it an effective and promising prodrug for PDT.
Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with limited treatment options and a poor prognosis. Its defining features include rapid proliferation, invasive capacity, and resistance to therapy. Bioinformatics analyses using TCGA and UALCAN datasets were conducted to assess MXRA8 and ELF3 expression and their association with patient survival. The expression levels were validated through qPCR and western blotting. Functional assays, including proliferation, migration, and invasion tests, were performed after silencing or overexpressing MXRA8 and ELF3. Chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assays determined ELF3’s role in regulating MXRA8 transcription. An in vivo xenograft model was used to evaluate the effects of ELF3 and MXRA8 on tumor growth. MXRA8 expression was significantly elevated in GBM tissues and associated with reduced overall survival. Functional analyses revealed that MXRA8 knockdown inhibited oncogenic traits. Moreover, ELF3 was overexpressed in GBM tissues and positively correlated with MXRA8 expression. ChIP and dual-luciferase assays confirmed that ELF3 binds to the MXRA8 promoter and activates its transcription. Rescue experiments showed that MXRA8 overexpression could reverse the tumor-suppressive effects of ELF3 knockdown. In vivo, silencing ELF3 or MXRA8 inhibited tumor growth and proliferation. This study suggests that the ELF3-MXRA8 axis may be a critical driver of GBM progression, with ELF3 promoting tumor growth and invasion through transcriptional activation of MXRA8.
20 October 2010 in Academic Journal of Second Military Medical University